Cholangiocarcinoma
Conditions
Interventions
Case series:ERCP/PTCD infusion drug packaging microparticles
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Patients must meet all the following criteria to be allowed to participate in clinical trials: 1. Patients with cholangiocarcinoma type I, type II and type III were diagnosed by pathology or clinical examination. 2. Patients without surgical indications, failure or intolerance of radiotherapy and chemotherapy; 3. No intravenous chemotherapy, radiotherapy and local administration of bile duct were performed in the past 4 weeks. 4. KPS = 60 points; 5. Aged 18 -85 years old; 6. Blood routine is generally normal; 7. Prothrombin function is generally normal(prothrombin international standardized ratio INR<1.5), no bleeding tendency; 8. BUN and Cr = 1.5 times normal upper limit(ULN) or creatinine clearance = 60mL/min; 9. No other serious cardiopulmonary diseases, etc.; 10. Patients agree to join the group and sign an informed consent form.
Exclusion criteria
Exclusion criteria: Patients with one of the following conditions can not participate or continue the clinical trial: 1. Breast-feeding, pregnant or preparing for pregnancy; 2. Patients with documented hypersensitivity to test sample ingredients or their analogues; 3. Patients with cognitive dysfunction or with poor compliance; 4. Participation in other clinical trials within 4 weeks; 5. Patients with PTCD and ERCP contraindications; 6. Patients with stents placed before treatment; 7. Patients combined with other severe, acute or chronic diseases that may interfere with the the results of this study; 8. Patients not fitted for this study determined by the investigators.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Quality of life assessment;Changes in bile drainage;Total lifetime; | — |
Primary
| Measure | Time frame |
|---|---|
| The imaging changes of bile duct stenosis before and after treatment were compared by MRCP.; | — |
Countries
China
Contacts
Public ContactFang Yao
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed